Journals / Annals of Medical Research / 2019 / Cilt: 26 - Sayı: 10

The impact of systemic inflammatory markers on survival in metastatic gastric cancer patients receiving first-line chemotherapy

Pages
2098–2104
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The Cox proportional hazards model was appliedto uncover the probable predictors of progression-free survival (PFS) and overall survival (OS).Results: According to univariate analysis, poor performance status, high NLR, high PLR, and anemia were significantly correlatedwith inferior OS receiving first-line palliative chemotherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The prognostic impact of elevated systemic inflammatory tools, including the neutrophil-lymphocyte ratio (NLR) and theplatelet-lymphocyte ratio (PLR), remains moot in cancer patients.
📊
Key Findings & Data:This research was performed to explore the predictive worth ofthese markers for prognoses in metastatic gastric cancer (mGC) patients receiving chemotherapy.Material and Methods: We retrospectively appraised 158 patients diagnosed with mGC between February 2009 and November 2017.According to threshold values that were identified by receiver operating characteristic (ROC) curve analysis, the NLR and PLR wereeach divided into two groups: ≤ 2.11 and >2.11, ≤ 158.8, and >158.8, respectively.
💡
Conclusion & Impact:The Cox proportional hazards model was appliedto uncover the probable predictors of progression-free survival (PFS) and overall survival (OS).Results: According to univariate analysis, poor performance status, high NLR, high PLR, and anemia were significantly correlatedwith inferior OS receiving first-line palliative chemotherapy.
🔬Design:Modeling & Simulation
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: The prognostic impact of elevated systemic inflammatory tools, including the neutrophil-lymphocyte ratio (NLR) and theplatelet-lymphocyte ratio (PLR), remains moot in cancer patients. This research was performed to explore the predictive worth ofthese markers for prognoses in metastatic gastric cancer (mGC) patients receiving chemotherapy.Material and Methods: We retrospectively appraised 158 patients diagnosed with mGC between February 2009 and November 2017.According to threshold values that were identified by receiver operating characteristic (ROC) curve analysis, the NLR and PLR wereeach divided into two groups: ≤ 2.11 and >2.11, ≤ 158.8, and >158.8, respectively. The Cox proportional hazards model was appliedto uncover the probable predictors of progression-free survival (PFS) and overall survival (OS).Results: According to univariate analysis, poor performance status, high NLR, high PLR, and anemia were significantly correlatedwith inferior OS receiving first-line palliative chemotherapy. High NLR, high PLR, and anemia were significantly correlated with poorPFS. In the multiple analysis, an elevated NLR was identified to be an independent predictor of inferior OS (OR: 2.70, 95% CI: 1.75-4.16, p

🔖

Cite This Article

İNANÇ, M., DOĞAN, E., COŞAR, R., BOZKURT, O., ÖZKAN, M., FIRAT, S. T. (2022). The impact of systemic inflammatory markers on survival in metastatic gastric cancer patients receiving first-line chemotherapy. Annals of Medical Research, Cilt: 26 - Sayı: 10, 2098–2104. https://ajindex.com/articles/447141

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Torre LA, Bray F, Siegel RL, et al. Global cancerstatistics, 2012. CA Cancer J Clin 2015;65:87-108
  2. Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol 2016;22:2403-14
  3. Ku GY, Ilson DH. Management of gastric cancer. Curr Opin Gastroenterol 2014;30:596-602
  4. Yang D, Hendifar A, Lenz C, et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J Gastrointest Oncol 2011;2:77-84
  5. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;17:CD004064
  6. Rajput S, Wilber A. Roles of inflammation in cancer initiation, progression, and metastasis.Front Biosci (Schol Ed). 2010;2:176-83 7. Lee S, Oh SY, Kim SH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 2013;13:350
  7. Jiang N, Deng JY, Liu Y, et al. The role of preoperative neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after radical resection for gastric cancer. Biomarkers 2014;19:444-51
  8. Chrom P, Stec R, Bodnar L, et al. Incorporating neutrophiltolymphocyte ratio and platelet-to-lymphocyte ratio in place of neutrophil count and platelet count improves prognostic accuracy of the international metastatic renal cell carcinoma database consortium model. Cancer Res Treat 2017;50:103-10
  9. Sun X, Liu X, Liu J, et al. Preoperative neutrophiltolymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer. Chin J Cancer 2016;35:57
  10. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open- label, randomised controlled trial. Lancet 2010;376:687-97
  11. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223-6
  12. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011;331:1565-70
  13. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7
  14. Coffelt SB, Wellenstein MD, de Visser KE.Neutrophils in cancer: neutral no more. Nat Rev Cancer 2016;16:431-46
  15. Jin H, Zhang G, Liu X, et al. Blood neutrophil‑lymph